Intrathecal effects of daclizumab treatment of multiple sclerosis - Wikidata - wikimedia - TriplyDB

Intrathecal effects of daclizumab treatment of multiple sclerosis

Intrathecal effects of daclizumab treatment of multiple sclerosis

http://www.wikidata.org/entity/Q35635127

about

Daclizumab for relapsing remitting multiple sclerosis Daclizumab for relapsing remitting multiple sclerosis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments Daclizumab therapy for multiple sclerosis Need for a paradigm shift in therapeutic approaches to CNS injury Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis The effects of interleukin-2 on immune response regulation.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis.Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.How implementation of systems biology into clinical trials accelerates understanding of diseases.A complex role of herpes viruses in the disease process of multiple sclerosis.Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation.Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis Radiologically isolated syndrome: watchful waiting vs. active treatment.CNS vasculitis in a patient with MS on daclizumab monotherapy The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis.Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation Natural killer cells and their receptors in multiple sclerosis.Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.Immunotherapy of multiple sclerosis: the state of the art.The role of natural killer cells in multiple sclerosis and their therapeutic implications.Drugs in development for relapsing multiple sclerosis.Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis.Monoclonal antibodies in treatment of multiple sclerosis.A critical appraisal of daclizumab use as emerging therapy in multiple sclerosis.Daclizumab for the treatment of multiple sclerosis.Human CD56bright NK Cells: An Update.Increased prevalence of lymphoid tissue inducer cells in the cerebrospinal fluid of patients with early multiple sclerosis.Safety concerns and risk management of multiple sclerosis therapies.Can new chemical therapies improve the management of multiple sclerosis in children?Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.Daclizumab for the treatment of relapsing-remitting multiple sclerosis.Efficiency of antibody therapy in demyelinating diseases.Pharmacodynamic effects of daclizumab in the intrathecal compartment.Natural killer cell subsets in cerebrospinal fluid of patients with multiple sclerosis.Daclizumab, an IL-2 modulating antibody for treatment of multiple sclerosis.Daclizumab.

P2860

Q24200496-A3D6E502-B443-4043-AC30-5B272B5FF23F Q24201637-B623AB87-F4A0-4E99-963B-E104B7B295E5 Q26776234-DE0120D1-1208-47A6-A3E0-FCC8FE561B3B Q26851694-008FCB85-8120-45A8-A1D1-A4291BED6E3E Q27022517-0A5BDA92-B14D-46F3-A272-C69D357ABE40 Q27025042-9DF6C0CD-0F29-494A-9AD3-7044DD7377CD Q28066677-8FE80C7C-5BF2-41D8-A714-D4C608B3B42D Q30252875-41FC5CBC-6F65-4022-B8A2-6757C5FE7DFB Q30699740-4F9FC7C0-FC7B-4EC8-95C8-E88DBC0895A6 Q30730505-58590995-0404-4B8E-BA08-37A5E837049D Q33589947-92265F70-C219-45A4-9311-6513B8666295 Q33755345-01F2C82B-9A13-40B2-A268-1342A44B89C1 Q33814843-69483DEE-12D5-49D7-94A7-87F85EA09616 Q34078589-81D370E5-3ECB-43EE-96E4-0412E211C343 Q34504952-1DA0767A-62AC-4795-9980-4556F51993D8 Q35619174-C842A913-F242-4B45-992E-BF1B1729C979 Q36188305-27A01E9D-7103-4219-B417-235F2242BE5C Q36661852-E1D9D778-CE52-4C5E-A4AB-764111FE3801 Q36748094-EC9EE7C4-2849-4F27-982F-3124D2697C4A Q36957280-3230665D-CD76-4EE5-A441-07D0F0198F91 Q37124504-F7B52218-6DDD-47DB-A794-A3195BDDB1E1 Q37354974-DC47AA04-14C3-45A4-BD73-1805C2CDF7C9 Q38083041-5ADE0D48-4653-49BA-A8A8-C24B6796288F Q38089599-B58EFDB2-9119-4E28-A14A-02FDFEFE8652 Q38101004-8F6E7A06-DF26-4789-AC2D-4E2912A31613 Q38111620-6C7017F9-59ED-4A95-8637-59EABA6E8FD5 Q38133865-3E1A85DF-46E9-4261-99C3-7DF08C6EB716 Q38397484-61CA3871-DD9B-4FC4-8A35-D6C49334C361 Q38604207-18C25A9D-5B0C-4C52-8A2A-B9A244E27EA2 Q38781384-5C5AEA4F-773E-40F3-99E2-AD28764267B5 Q38954794-747CF4E5-6FBC-46F3-AA02-EA4A7FC37429 Q39021781-61E0D6C8-534D-478C-80D4-BF848E3C6671 Q39024427-446E3C76-7EE5-4DBC-B56C-BD044B022FB2 Q39032832-E44E5D78-6A44-4426-9917-8EF0E2FDD596 Q39175716-01890BCD-EC4B-4F6A-9DFD-5A975F1B2F2A Q40045794-517BF577-278E-4BE0-B968-9FA717F0DF1A Q40962441-37BC6378-64FB-4087-AD17-CA39A10750CC Q41615056-C7C49AFD-1C03-4D60-BF32-DC6FB3DB04CE Q43905322-986DB9E2-4393-4F71-A82B-A4072D8208E4 Q46487963-8A3110A3-E87B-42A2-85C3-A7BCE061092F

P2860

Intrathecal effects of daclizumab treatment of multiple sclerosis

http://www.wikidata.org/entity/Q35635127

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Intrathecal effects of daclizumab treatment of multiple sclerosis

@ast

Intrathecal effects of daclizumab treatment of multiple sclerosis

@en

type

label

Intrathecal effects of daclizumab treatment of multiple sclerosis

@ast

Intrathecal effects of daclizumab treatment of multiple sclerosis

@en

prefLabel

Intrathecal effects of daclizumab treatment of multiple sclerosis

@ast

Intrathecal effects of daclizumab treatment of multiple sclerosis

@en

P1433

Q35635127-02FCA4F9-2C44-4F99-AC1A-B1253D617B87

P1476

Q35635127-787ADF50-97A7-4719-B8CD-CD62EF70B34C

P2093

Q35635127-1C15A53A-A52E-44FC-8470-F415F782E066

Q35635127-49B92506-DAD2-435E-85A0-02E034996B43

Q35635127-77F2348E-6B14-4456-A76F-234C68E5E091

Q35635127-7C3F061A-6188-4508-B861-922C2AE805F1

Q35635127-7D0F17A6-BCF3-4121-AA24-82B8FF987746

Q35635127-E0697451-6F02-4FC4-A422-6236BB98FD54

Q35635127-ED60C425-9D31-4BB3-95AE-8845823B1C63

Q35635127-F6AAD400-01F3-4FD1-8233-F35BCC9083A0

P2860

Q35635127-1C85ABE5-A0D1-4479-B521-54313C90253A

Q35635127-21FDCCB2-6A8B-405D-993B-2B7F94AEAE58

Q35635127-31566112-1738-400E-8D00-ED272ABC515C

Q35635127-35A6C778-D997-49CC-84C5-4B2BD730F42C

Q35635127-4D1B4C54-C906-4F3D-9E74-57F8A6A2484B

Q35635127-63023749-3FAB-4D70-B530-363E07BE30A8

Q35635127-63E7243F-414D-4120-B44A-FF2B1300CBD7

Q35635127-8079E6EE-3E18-4131-BE80-083A0CEC72A8

Q35635127-894DADFD-0B4A-4969-B147-65FD95C5F998

Q35635127-8C375C8C-EC33-4747-916F-CC76F2F0A579

P304

Q35635127-6903D2BC-6881-4CEF-9CC3-6A02817F7870

P31

Q35635127-A0488255-A932-4491-9111-1A42B5B32ED9

P356

Q35635127-5829940D-FF16-4D79-9649-CCD85FE1E39D

P407

Q35635127-73E6CE5E-3FCA-4D78-B784-DCA878F64AD4

P433

Q35635127-1F661537-6B83-4DC9-A593-6C535A147819

P478

Q35635127-011ACD59-C82B-46F9-B978-DE4FDE6C075F

P577

Q35635127-761E05E0-38DA-457C-BEB4-57B724354EBF

P5875

Q35635127-4360C6A6-6ACE-4E19-8F83-2838DF6665C6

P698

Q35635127-722329CF-D01F-4538-9AE6-C06BF1A92425

P921

Q35635127-29DF421F-739D-423D-A576-B591454E897D

P932

Q35635127-30963B2E-A6BA-4573-AD8D-8C5C015E84E4

P356

WNL.0B013E318239F7EF

P1433

P1476

Intrathecal effects of daclizumab treatment of multiple sclerosis

@en

P2093

B Bielekova

http://www.w3.org/2001/XMLSchema#string

G Blevins

http://www.w3.org/2001/XMLSchema#string

H McFarland

http://www.w3.org/2001/XMLSchema#string

J Ohayon

http://www.w3.org/2001/XMLSchema#string

M L Herman

http://www.w3.org/2001/XMLSchema#string

N Richert

http://www.w3.org/2001/XMLSchema#string

R Martin

http://www.w3.org/2001/XMLSchema#string

T A Waldmann

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.

Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury

Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood

Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology.

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.

P304

1877-1886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E318239F7EF

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51792311

http://www.w3.org/2001/XMLSchema#string

P698

22076546

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

3246406

http://www.w3.org/2001/XMLSchema#string